GlaxoSmithKline

ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025

08 Jul 2025

Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (CAB+RPV LA) for HIV treatment.

GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

07 Jul 2025

GSK plc today announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals

Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5

25 Jun 2025

Price reduction is commitment by Bharat Biotech made possible through partnership with GSK.

Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

24 Jun 2025

Submission based on data from positive GLISTEN phase III trial

Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease

20 Jun 2025

If approved, GSK’s RSV vaccine would be the first available in Japan to help protect this group

GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older

13 Jun 2025

Regulatory decision anticipated H1 2026.

GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development

12 Jun 2025

GSK plc announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited.

02 June 2025

02 Jun 2025

Application based on data from positive GLISTEN phase III trial

Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

02 Jun 2025

Application based on data from positive GLISTEN phase III trial

GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio

29 May 2025

GSK today announced that data across the oncology pipeline and portfolio will be presented at ASCO and EHA.

View details about the software product Informachine News Trackers